Rejeneron Pharmacist Buy 23andme assets for 6 256 million after the collapse of the genetic company

Height is a box with a saliva tube that promised to reveal the secrets of genetic and ancestral. Davels auctioning off the fall and the buyer. A. 23andmeIt is worth $ 6 billion, sold for 6 256 million Regeneron PharmaceuticalsThe end of a era for one of the well -known startups in the individual health field.

Founded by Biochemistry Anne Vozsiki, this company is famous for its submission Direct genetic tests to the userAllows the anterior to diseases, ancestors and hereditary symptoms with a normal saliva pattern. But never gain profit and faced a legacy of financial crises, Data Leaks And extreme team cuts.

23 and never acted in Brazil. Here, Marx Meadna and Races are well known.

What did Regeneron take?

This package includes 23andme personal genetic services, its overall health and research departments, as well as a Bank with millions of genetic patterns from clients. Not in acquisition Lemonide HealthVertical telemedicine that works separately.

This transaction still depends on the legal and control approval scheduled for the third quarter of 2025. Estimated at US $ 63 billion, one of the pioneers in the development of American Pharmacist Regeneron A Treatment of Covid-19.

23andme how did you collapse?

23 AndMe opened the capital in 2021 a Spock And never got a profit. He tried to be varied, betting on the development of Drugs Shades based on genetic data, but left the project last year. By 2023, a leak displayed information from 6.9 million clients and as a result court agreement US $ 30 million.

In the end of 2024, the situation worsened: the two attempts to repay the founder actions failed and 40% fired employees. In March 2025, The official request of Bankruptcy In the US. Sent documents Sec Revealed US $ 2.3 billion debts and only US $ 126 million cash.

Anne Vozsi is the command left in the same month. The then Chief Financial Officer Joe Selsavege thought it was interim.

What comes now?

Rejeneron sees a way of expanding his programs in the personalized medicine Shadam Genetic mapping. “We want to use this data to improve the treatment and prevention of the disease,” said the company’s classical director George Ankopaulos in an official statement.

The company said it hopes to continue the operation by respecting the 23andme’s privacy policies and to target the consumer. The independent ombudsman appointed by the court should follow the new step to ensure Protection of genetic data Consumers.

Source link